7-day Study of the Safety, Efficacy and the Pharmacokinetic and Pharmacodynamic Properties of Oral Rivaroxaban in Children From Birth to Less Than 6 Months With Arterial or Venous Thrombosis
Phase of Trial: Phase I/II
Latest Information Update: 15 Mar 2018
At a glance
- Drugs Rivaroxaban (Primary)
- Indications Arterial thrombosis; Catheter thrombosis; Venous thrombosis
- Focus Pharmacodynamics; Pharmacokinetics
- Acronyms EINSTEIN; Einstein Jr
- Sponsors Bayer; Bayer HealthCare
- 07 Feb 2018 Status changed from recruiting to completed.
- 01 Feb 2018 The study has been completed in Germany.
- 26 Jan 2018 The study has been completed in Austria.